论文部分内容阅读
目的:初步探讨索拉菲尼联合化疗治疗FLT3-ITD突变的复发急性单核细胞白血病后行半相合造血干细胞移植的安全性与有效性,提高对新的分子靶向治疗的认识。方法:报告1例FLT3-ITD突变的复发急性单核细胞白血病患者的临床症状、实验室特征,应用索拉菲尼联合化疗诱导治疗后进行半相合造血干细胞移植的过程。结果:患者经过索拉菲尼联合化疗后,骨髓学完全缓解,并成功进行半相合造血干细胞移植。治疗过程顺利,患者可耐受药物不良反应。结论:索拉非尼联合化疗在难治复发的FLT3-ITD阳性AML患者有一定疗效,可为该类患者行异基因造血干细胞移植提供较好时机。
Objective: To investigate the safety and efficacy of sorafenib combined with chemotherapy in the treatment of recurrent acute monocytic leukemia with FLT3-ITD mutation and to improve the understanding of new molecular targeted therapy. Methods: The clinical symptoms and laboratory characteristics of one FLT3-ITD-mutated recurrent acute monocytic leukemia were reported. Semi-coincident hematopoietic stem cell transplantation was performed after induction with sorafenib plus chemotherapy. Results: After the combination of sorafenib and chemotherapy, myelopathy was completely relieved and haploidentical hematopoietic stem cell transplantation was successfully performed. The course of treatment goes well and patients can tolerate adverse drug reactions. Conclusion: Sorafenib combined with chemotherapy in patients with refractory and relapsed FLT3-ITD positive AML patients have a certain effect, which may provide a good opportunity for allogeneic hematopoietic stem cell transplantation in these patients.